In a nutshell
This study reviewed the effectiveness of citicoline (CIT; Neurocoline) in improving symptoms of Parkinson’s disease (PD). Researchers suggested that CIT improved the symptoms of these patients.
Some background
More than 10 million people worldwide live with PD. It affects brain cells which lose their abilities to control body functions. This causes symptoms such as tremors. Levodopa is the standard treatment. However, long-term treatment with levodopa is associated with negative side effects. Therefore, new therapies could improve the long-term treatment outcomes of these patients.
CIT is a substance normally found in the body. When given as a supplement it increases the levels of a chemical involved in brain functions. Prior studies showed that CIT protects the brain in animals and humans. It has been shown to improve mental function in patients with PD. However, the effectiveness of CIT in improving symptoms and quality of life of patients with PD is still not clear.
Methods & findings
This study reviewed 7 other studies with information about patients with PD. These patients received CIT together with their primary treatment.
Participants taking CIT improved rigidity, movement, tremor, handwriting, and speech. CIT allowed for the reduction of levodopa intake by 50%. Patients receiving CIT also had a significant improvement in mental function.
The bottom line
This study concluded that CIT is a good and safe addition to the treatment of patients with PD.
The fine print
This study analyzed very different studies. Most of these studies were fairly old. New studies are needed to confirm these results.
Published By :
Clinical therapeutics
Date :
Dec 03, 2020
